UBS has reiterated its 'Buy' rating for Sanofi, with a target price of 110 euros, ahead of the company's upcoming quarterly results on October 25.

Analyst Jo Walton emphasized the importance of monitoring the ongoing success of Dupixent and the market acceptance of Beyfortus in the upcoming earnings report. These key products reflect Sanofi's strategic positioning in the pharmaceutical market as it faces competition and aims to sustain growth.

Investors are eagerly awaiting the quarterly figures to assess the company's performance and future prospects.